VRDN

NASDAQ 已收盘

Viridian Therapeutics

31.44 USD
▲+1.32+4.38%
盘后 32.00 +1.78%
2026-11-19
市值
$3.40B
市盈率
—
EPS
-3.80
股息率
—
52 周区间
13.18 – 34.29
成交量
4.02M
Beta
1.07
目标价
42.76
52W 低 13.1852W 高 34.29
价格走势

公司简介

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o...